The Phase 2 ALPESTRIA-1 clinical study has started with Vonafexor on Alport syndrome
The ALPESTRIA-1 Phase 2 clinical study (NCT06425055) is an open-label, single arm, fixed dose escalation of the investigational drug Vonafexor. This study is a proof-of-concept trial of Vonafexor safety, its effects on kidney function in subjects with at risk of progression Alport syndrome. The study aims to recruit 20 patients in the US and EU (France, Spain and Germany).
The first site for patient recruitment is now open in Idaho (US) and more sites will open in the coming weeks.
ASN Kidney Week 2024
23-27 October 2024
San Diego, CA
ENYO Pharma will attend the world’s premier nephrology meeting of the American Society of Nephrology, ASN Kidney Week.
https://www.asn-online.org/education/kidneyweek/2024/important-dates.aspx
Alport Connect 2024, the annual Alport syndrome patient and family meeting in US
27-28 July 2024
Denver, CA
ENYO Pharma is sponsoring and will attend Alport Connect 2024 organized by the American Alport Syndrome Foundation (ASF), the Alport syndrome patient-led non-profit organization in the US.
ENYO Pharma will meet patients and their families to present its starting Phase 2 “ALPESTRIA-1” clinical study with Vonafexor in Alport syndrome patients.
The 2024 international workshop on Alport syndrome
14-16 March, 2024 – Nicosia, Cyprus
ENYO Pharma is sponsoring and will attend The 2024 International Workshop on Alport syndrome organized by the Alport Syndrome Alliance, an international patient-driven collaboration.
ENYO Pharma announces a €39 million Series C financing and FDA clearance to advance Vonafexor in a Phase 2 clinical trial for patients with Alport syndrome
ENYO Pharma announces a €39 million Series C financing and FDA clearance to advance Vonafexor in a Phase 2 clinical trial for patients with Alport syndrome
Latest Press Release 